Xenical

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
10-05-2023
Produktens egenskaper Produktens egenskaper (SPC)
10-05-2023

Aktiva substanser:

orlistat

Tillgänglig från:

CHEPLAPHARM Arzneimittel GmbH

ATC-kod:

A08AB01

INN (International namn):

orlistat

Terapeutisk grupp:

Antiobesity preparations, excl. diet products

Terapiområde:

Obesity

Terapeutiska indikationer:

Xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m2, or overweight patients (BMI > 28 kg/m2) with associated risk factors.Treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight as measured at the start of therapy.

Produktsammanfattning:

Revision: 25

Bemyndigande status:

Authorised

Tillstånd datum:

1998-07-29

Bipacksedel

                                21
B. PACKAGE LEAFLET
22
PACKAGE LEAFLET: INFORMATION FOR THE USER
XENICAL 120MG HARD CAPSULES
Orlistat
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, please ask your doctor or your
pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any of the side effects, talk to your doctor or pharmacist.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Xenical is and what it is used for
2.
What you need to know before you take Xenical
3.
How to take Xenical
4.
Possible side effects
5.
How to store Xenical
6.
Contents of the pack and other information
1.
WHAT XENICAL IS AND WHAT IT IS USED FOR
Xenical is a medicine used to treat obesity. It works in your
digestive system to block about one-third
of the fat in the food you eat from being digested.
Xenical attaches to the enzymes in your digestive system (lipases) and
blocks them from breaking
down some of the fat you have eaten during your meal. The undigested
fat cannot be absorbed and is
eliminated by your body.
Xenical is indicated in the treatment of obesity in conjunction with a
low calorie intake diet.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE XENICAL
DO NOT TAKE XENICAL
•
if you are allergic (hypersensitive) to orlistat or to any of the
other ingredients of Xenical,
•
if you have chronic malabsorption syndrome (insufficient absorption of
nutrients from
alimentary tract),
•
if you have cholestasis (liver disorder)
•
if you are breast-feeding
WARNINGS AND PRECAUTIONS
Weight loss may also affect the dose of medicines taken for other
conditions (e.g. high cholesterol or
diabetes). Be sure to discuss these and other medicines you may be
taking with your doctor. Losing
weight may mean you need adjustments to t
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Xenical 120 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each hard capsule contains 120 mg orlistat.
For a full list of excipients, see 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule.
The capsule has a turquoise cap and turquoise body bearing the imprint
of “XENICAL 120”.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Xenical
is indicated in conjunction with a mildly hypocaloric diet for the
treatment of obese patients
with a body mass index (BMI) greater or equal to 30 kg/m², or
overweight patients (BMI > 28 kg/m²)
with associated risk factors.
Treatment with orlistat should be discontinued after 12 weeks if
patients have been unable to lose at
least 5 % of the body weight as measured at the start of therapy.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Adults
The recommended dose of orlistat is one 120 mg capsule taken with
water immediately before, during
or up to one hour after each main meal. If a meal is missed or
contains no fat, the dose of orlistat
should be omitted.
The patient should be on a nutritionally balanced, mildly hypocaloric
diet that contains approximately
30 % of calories from fat. It is recommended that the diet should be
rich in fruit and vegetables. The
daily intake of fat, carbohydrate and protein should be distributed
over three main meals.
Doses of orlistat above 120 mg three times daily have not been shown
to provide additional benefit.
The effect of orlistat results in an increase in faecal fat as early
as 24 to 48 hours after dosing. Upon
discontinuation of therapy, faecal fat content usually returns to
pre-treatment levels, within 48 to 72
hours.
Special populations
The effect of orlistat in patients with hepatic and/or renal
impairment, children and elderly patients has
not been studied.
There is no relevant indication for use of Xenical in children.
4.3
CONTRAINDICATIONS
-
Hypersensitivity to the active substance or to any of the excipients.
-
Chronic malabsorption syndrome.
-
Choles
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 10-05-2023
Produktens egenskaper Produktens egenskaper bulgariska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 13-11-2008
Bipacksedel Bipacksedel spanska 10-05-2023
Produktens egenskaper Produktens egenskaper spanska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 13-11-2008
Bipacksedel Bipacksedel tjeckiska 10-05-2023
Produktens egenskaper Produktens egenskaper tjeckiska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 13-11-2008
Bipacksedel Bipacksedel danska 10-05-2023
Produktens egenskaper Produktens egenskaper danska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 13-11-2008
Bipacksedel Bipacksedel tyska 10-05-2023
Produktens egenskaper Produktens egenskaper tyska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 13-11-2008
Bipacksedel Bipacksedel estniska 10-05-2023
Produktens egenskaper Produktens egenskaper estniska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 13-11-2008
Bipacksedel Bipacksedel grekiska 10-05-2023
Produktens egenskaper Produktens egenskaper grekiska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 13-11-2008
Bipacksedel Bipacksedel franska 10-05-2023
Produktens egenskaper Produktens egenskaper franska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 13-11-2008
Bipacksedel Bipacksedel italienska 10-05-2023
Produktens egenskaper Produktens egenskaper italienska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 13-11-2008
Bipacksedel Bipacksedel lettiska 10-05-2023
Produktens egenskaper Produktens egenskaper lettiska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 13-11-2008
Bipacksedel Bipacksedel litauiska 10-05-2023
Produktens egenskaper Produktens egenskaper litauiska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 13-11-2008
Bipacksedel Bipacksedel ungerska 10-05-2023
Produktens egenskaper Produktens egenskaper ungerska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 13-11-2008
Bipacksedel Bipacksedel maltesiska 10-05-2023
Produktens egenskaper Produktens egenskaper maltesiska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 13-11-2008
Bipacksedel Bipacksedel nederländska 10-05-2023
Produktens egenskaper Produktens egenskaper nederländska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 13-11-2008
Bipacksedel Bipacksedel polska 10-05-2023
Produktens egenskaper Produktens egenskaper polska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 13-11-2008
Bipacksedel Bipacksedel portugisiska 10-05-2023
Produktens egenskaper Produktens egenskaper portugisiska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 13-11-2008
Bipacksedel Bipacksedel rumänska 10-05-2023
Produktens egenskaper Produktens egenskaper rumänska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 13-11-2008
Bipacksedel Bipacksedel slovakiska 10-05-2023
Produktens egenskaper Produktens egenskaper slovakiska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 13-11-2008
Bipacksedel Bipacksedel slovenska 10-05-2023
Produktens egenskaper Produktens egenskaper slovenska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 13-11-2008
Bipacksedel Bipacksedel finska 10-05-2023
Produktens egenskaper Produktens egenskaper finska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 13-11-2008
Bipacksedel Bipacksedel svenska 10-05-2023
Produktens egenskaper Produktens egenskaper svenska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 13-11-2008
Bipacksedel Bipacksedel norska 10-05-2023
Produktens egenskaper Produktens egenskaper norska 10-05-2023
Bipacksedel Bipacksedel isländska 10-05-2023
Produktens egenskaper Produktens egenskaper isländska 10-05-2023
Bipacksedel Bipacksedel kroatiska 10-05-2023
Produktens egenskaper Produktens egenskaper kroatiska 10-05-2023

Sök varningar relaterade till denna produkt

Visa dokumenthistorik